B Cell Engineering Service for Anti-HIV Antibody Delivery

A CRISPR-Cas Cure for HIV

HIV infects cells of the host immune system, which can be targeted and edited through gene therapy. A gene-editing platform based on the clustered regularly spaced palindromic repeat-cas system (CRISPR-Cas) has been recognized as a promising tool for developing gene therapies for HIV infection. It is a promised approach that antibody gene transfer immunoprophylaxis, which involves viral delivery of genes that encode broadly neutralizing antibodies (bNAbs). Besides, bNAb gene delivery to stem and progenitor cells in humanized mice has been described.

Fig.1 DNA- and RNA-targeting CRISPR-Cas systems. (Hussein, et al., 2023)

Our B Cell Engineering Service for Anti-HIV Antibody Delivery

Creative Biolabs engineers primary B cells with precise genome editing techniques, which replace endogenously encoded antibodies of primary human B cells with antibodies that target HIV. Engineered B cells enable immune memory and clonal selection, which may help address viral variability and counteract viral escape.

Fig.2 B cell engineering service for anti-HIV antibody delivery. (Creative Biolabs)

Published Data

Paper Title: Engineered B cells expressing an anti-HIV antibody enable memory retention, isotype switching and clonal expansion

Technology: CRISPR/Cas9-based Genome Editing

Therapeutic Antibody: Anti-HIV Antibody

Journal: Cell

IF: 14.919

Published: 2020

Background: B cell engineering therapy can overcome the challenges, such as bNAbs therapy which chronically administered at a higher cost. This research engineered B cells by CRISPR/Cas9 to express anti-HIV antibodies which are capable of secreting high antibody titers. This shows that B cells can be engineered into what could be a living and evolving drug for HIV.

Results: The engineered B cells enable immunological memory and clonal selection that may contribute to addressing viral variability between patients and to counteracting viral escape.

Following are some results displayed that refer to B cell engineering for Anti-HIV antibody delivery in this article:

Fig.3 The protocol of the human and mouse B cell engineering. (Nahmad, et al., 2020)

Fig.4 Flow cytometry of binding of the HIV gp120 antigen by the 3BNC117 BCR. (Nahmad, et al., 2020)

Fig.5 Adoptively transferred engineered B cells enable memory retention upon immunization. (Nahmad, et al., 2020)

Fig.6 Adoptively transferred engineered B cells can clonal expansion upon immunization and undergo CSR. Nahmad, et al., 2020)

Frequently Asked Questions

Q1: Why choose B cell engineering for anti-HIV antibody delivery?

A: The engineered B cell will overcome the following challenges.

• Long-term antiretroviral therapy cannot eradicate HIV infection.
• bNAbs can suppress viremia, but have to be chronically administered at a higher cost.
• bNAbs can be constitutively expressed from muscle, but antidrug antibodies (ADA) are often developed.
• Antibodies expressed from muscle undergo neither class transition recombination (CSR) nor affinity maturation.

Q2: What is the approach of CRISPR/Cas anti-HIV?

A: CRISPR/Cas anti-HIV approaches used to protect cells from HIV infection are shown as follows.

Fig.7 CRISPR/Cas anti-HIV approaches. (Maslennikova, et al., 2022)

Q3: What other diseases can B cell engineering technology be used for?

A: As a platform technology, B cell engineering can be applied to diverse persistent infections as well as to the treatment of congenital disorders, autoimmune diseases and cancer. For more information on this, please browse below：

More B Cell Engineering Services for Anti-Viruses Antibody Delivery

We offer professional consultation guidance before, during and after the project, please contact us for your tailored solution.

1. Nahmad, A.D.; et al. Engineered B cells expressing an anti-HIV antibody enable memory retention, isotype switching and clonal expansion. Nat Commun. 2020.
2. Maslennikova, A.; et al. Application of CRISPR/Cas genomic editing tools for HIV therapy: toward precise modifications and multilevel protection. Front Cell Infect Microbiol. 2022, 12: 880030.
3. Hussein, M.; et al. A CRISPR-Cas cure for HIV/AIDS. Int J Mol Sci. 2023, 24(2): 1563.

Related Sections:

• Anti-COVID-19 Antibody Delivery
• Anti-RSV Antibody Delivery
• Anti-Influenza Virus Antibody Delivery
• Anti-EBV Antibody Delivery